トジナメラン Pfizer-BioNTech vaccine BNT162b2


Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults.
 Mulligan MJ, Lyke KE, Kitchin N, et al. 〔Nature. 2020 Oct;586(7830):589-593〕(査読済み)


Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
 Walsh EE, Frenck RW Jr, Falsey AR, et al. 〔N Engl J Med. 2020 Dec 17;383(25):2439-2450〕(査読済み)


Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
 Polack FP, Thomas SJ, Kitchin N, et al. 〔N Engl J Med. 2020 Dec 31;383(27):2603-2615〕(査読済み)


BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
 Sahin U, Muik A, Vogler I, et al. 〔medRxiv. 2020 Dec 11〕(査読前)


Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
 Muik A, Wallisch AK, Sänger B, et al. 〔Science. 2021 Jan 29:eabg6105〕(査読済み)


The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence
 Chodick G, Tene L, Patalon T, et al. 〔medRxiv. 2021 Jan 29〕(査読前)


Decreased SARS-CoV-2 viral load following vaccination
 Levine-Tiefenbrun M, Yelin I, Katz R, et al. 〔medRxiv. 2021 Feb 08〕(査読前)


Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021
 Abu Jabal K, Ben-Amram H, Beiruti K, et al. 〔Euro Surveill. 2021 Feb;26(6)〕(査読済み)


Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine
 Krammer F, Srivastava K, the PARIS team, et al. 〔medRxiv. 2021 Feb 01〕(査読前)


Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1
 Stamatatos L, Czartoski J, et al. 〔medRxiv. 2021 Feb. 08〕(査読前)